



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website. : www.fermentabiotech.com



F.No.:908

November 11, 2025

Corporate Relations
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Press Release

Ref: Scrip Code 506414

Please find enclosed herewith a 'Press Release' issued by the Company regarding financials of H1FY26.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Fermenta H1FY26 Consolidated Revenues up 57% YoY; Net profit up 664% YOY

BSE: 506414	Bloomberg: FERMENTA:IN	Reuters: FERM.BO
-------------	------------------------	------------------

- Consolidated Revenue for H1FY26 INR 280.7 crore, up by INR 101.8 crore YoY
- Consolidated EBITDA for H1FY26 INR 69.1 crore, up 173% YoY
- Q2FY26 Consolidated Revenues INR 135.7 crore, up 39% YoY; down 6% QoQ

Mumbai, 11 November 2025: Fermenta Biotech Limited, India's leading manufacturer of pre-mium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the half year ended 30 September 2025 was INR 275.2 crore, up 59% from the same year-ago period; EBITDA for half year ended 30 September 2025 was INR 67.2 crore up 155% from the same year-ago period.

Key financials (consolidated) without real estate

	Q2FY26	H1FY26
Revenue	INR 133.7 crore (up 41% YoY, down 5% QoQ)	INR 275.2 crore (up 59% YoY)
EBITDA	INR 31.9 crore (up 49% YoY, down 10% QoQ)	INR 67.2 crore (up 155% YoY)

Key financials (consolidated) with real estate

	Q2FY26	H1FY26
Revenue	INR 135.7 crore (up 39% YoY, down 6% QoQ)	INR 280.7 crore (up 57% YoY)
EBITDA	INR 32.1 crore (up 48% YoY, down 13% QoQ)	INR 69.1 crore (up 173% YoY)
Profit after tax	INR 18.0 crore (up 62% YoY, down 17% QoQ)	INR 39.6 crore (up 664% YoY)
EPS (diluted)	INR 6.43	INR 13.87

Revenue mix (consolidated)

	H1FY26 (INR crore)	H1FY25 (INR crore)	YoY change (%)
Nutrition Business			
Vitamin D3 – Human Nutri- tion	158.8	88.3	+80%
Vitamin D3 – Animal Nutri- tion	46.2	32.2	+44%
Others	15.2	19.6	-23%
Other Business			
Other APIs and Intermediates	22.9	18.1	+27%
Green Chemistry Solutions / Enzymes	3.5	3.9	-11%
Environmental Solutions	15.1	6.6	+127%
Other Income	17.5	10.1	+73%
Value Unlocking			
Real Estate	1.6	-	-

Performance highlights

- Human nutrition segment volumes grew 74% growth over H1FY25
- Animal nutrition segment volumes grew 6% and average realization rose 35% over H1FY25
- "Other API" segment grew 27% YoY on the back of unusually higher demand for our niche product from a customer
- Other Income includes non-recurring insurance claim received amounting to INR 2.7 crore in Q1FY26 and H1FY26
- Our German toll manufacturing subsidiary's H1FY26 revenue was INR 34.3 crores, up 194% YoY from the same period a year ago, with EBITDA at INR 7.7 crore, up 103% YoY. Our US trading business subsidiary's H1FY26 revenue was INR 30.3 crore, up 68% from a year ago with EBITDA at INR 0.1 crore loss, against INR 0.6 crore loss in the same period a year ago.
- During the current quarter ended 30 September 2025, cost of material consumed includes reversal of provision of INR 5.06 crore and, for the quarter ended 30 September 2024, included reversal of provision of INR 4.14 crore towards semi-finished inventory used in the production of animal feed.
- In September 2025, the Indian Patent Office formally granted a patent for the proprietary plant-based Vitamin D3 manufacturing process created in-house by Fermenta's R&D.
- The Board of Directors of the Company at its meeting held on 19 September 2025 approved transfer of the 'Environment Division' as a going concern on a slump sale basis, effective 01 October 2025, to its wholly owned subsidiary, Fermenta Environment Solutions Private Limited, for a sales consideration of INR 19 crore.

Commenting on the results, Prashant Nagre, Managing Director, said:

"The turnaround of FY25 was further confirmed in H1FY26. While core revenue growth, excluding that from real estate unlocking, in FY25 over FY24 was 57%, H1FY26 excluding that from real estate unlocking, the revenue was already 64.5% of that achieved in full FY25.

EBITDA in H1FY26, excluding real estate, was 81% of the total EBITDA for FY25.

While human nutrition volumes grew by 48% in FY25 over FY24, we have further seen the volumes grow by 74% in H1FY26 over H1FY25.

The process patent for the production of completely vegan and vegetarian-friendly Vitamin D3 will help Fermenta capture emerging global opportunities across nutraceuticals and food fortification sectors, where sustainable, plant-derived ingredients command premiums and growing market share. We are going through the process of regulatory approvals.

The transfer of our environmental solutions portfolio to a dedicated subsidiary creates a focused entity that can target accelerated growth in this critical sector. This strategic move reflects Fermenta's commitment to applying our decades-honed capabilities--it perfectly complements our core business and reinforces our strategy of sustainable innovation"

Geographical Revenue Mix (consolidated) excluding real estate value unlocking

	H1FY26	H1FY25	Change (%)
India	40%	41%	-1%
Europe	29%	27%	+2%
North America	13%	15%	-2%
Others	18%	17%	+1%

About

Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta's comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provides research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions.

Disclaimer

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ("Company" or "FBL" or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not neces-

sarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

--ends